Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...

NovoCure faces margin pressure, slow launches, and adoption hurdles beyond GBM, despite revenue beats and pipeline hopes.

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently talked about. Cramer mentioned the stock and said that he liked its quarter. He remarked: “What do we make of the numbers that we ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Melbourne-based biotech VC Boson Ventures has raised $10 million of a target $30 million fund and is positioning itself as a ...